ACARIX AB Financials Acarix AB Deutsche Boerse AG
Equities
7AC
SE0009268717
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.029 EUR | +9.02% |
|
+14.17% | +90.79% |
| 05-27 | Acarix AB Appoints Jeff Thomas as the New Head of US Sales, Effective June 1, 2024 | CI |
| 05-14 | Transcript : Acarix AB, Q1 2024 Earnings Call, May 14, 2024 |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 65.91 | 167.1 | 219.7 | 71.81 | 139.9 | 301.2 | - | - |
| Enterprise Value (EV) 1 | 12.16 | 167.1 | 203.9 | 60.65 | 139.9 | 301.2 | 301.2 | 301.2 |
| P/E ratio | -0.7 x | -2.32 x | -2.36 x | - | -1.19 x | - | - | - |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 35.5 x | - | 58.4 x | 12.3 x | 22.4 x | 5.55 x | 1.71 x | 1.18 x |
| EV / Revenue | 35.5 x | - | 58.4 x | 12.3 x | 22.4 x | 5.55 x | 1.71 x | 1.18 x |
| EV / EBITDA | -1.56 x | - | -4.55 x | -0.98 x | -1.88 x | -8.83 x | 4.42 x | 2.95 x |
| EV / FCF | -1.48 x | - | -4.57 x | -0.96 x | -1.72 x | -5.79 x | -100 x | - |
| FCF Yield | -67.6% | - | -21.9% | -104% | -58.2% | -17.3% | -1% | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 51,694 | 141,045 | 251,972 | 251,972 | 737,189 | 973,170 | - | - |
| Reference price 2 | 1.275 | 1.185 | 0.8720 | 0.2850 | 0.1898 | 0.3095 | 0.3095 | 0.3095 |
| Announcement Date | 20-02-20 | 21-04-20 | 22-02-17 | 23-02-16 | 24-02-15 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1.857 | - | 3.76 | 5.822 | 6.241 | 54.3 | 176.6 | 256.1 |
| EBITDA 1 | -42.33 | - | -48.32 | -73.44 | -74.46 | -34.1 | 68.2 | 102 |
| EBIT 1 | -46.44 | - | -51.7 | -76.48 | -77.55 | -39.8 | 50.2 | 84.2 |
| Operating Margin | -2,501.02% | - | -1,374.89% | -1,313.55% | -1,242.64% | -73.3% | 28.43% | 32.88% |
| Earnings before Tax (EBT) 1 | -46.43 | - | -51.73 | -76.98 | -77.84 | -54 | 2 | - |
| Net income 1 | -46.46 | -41.5 | -51.73 | -76.98 | -77.84 | -54 | 2 | - |
| Net margin | -2,501.83% | - | -1,375.82% | -1,322.31% | -1,247.22% | -99.45% | 1.13% | - |
| EPS | -1.830 | -0.5100 | -0.3700 | - | -0.1600 | - | - | - |
| Free Cash Flow 1 | -44.53 | - | -48.05 | -75.02 | -81.37 | -52 | -3 | - |
| FCF margin | -2,398.12% | - | -1,277.93% | -1,288.56% | -1,303.73% | -95.76% | -1.7% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 20-02-20 | 21-04-20 | 22-02-17 | 23-02-16 | 24-02-15 | - | - | - |
1SEK in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q3 | 2022 Q4 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 1.653 | 1.54 | 1.573 | 1.174 | 1.552 | 6.5 | 19 | 27.2 |
| EBITDA 1 | - | - | - | -16.43 | -21.28 | -14.22 | -13.8 | -4.4 | 1 |
| EBIT 1 | - | -22.61 | - | -17.23 | -22 | -14.93 | -15 | -6.2 | -1 |
| Operating Margin | - | -1,368% | - | -1,095.1% | -1,873.76% | -961.79% | -230.77% | -32.63% | -3.68% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - |
| Net income | -21.11 | - | -22 | - | - | - | - | - | - |
| Net margin | - | - | -1,428.83% | - | - | - | - | - | - |
| EPS | -0.0800 | - | -0.0500 | -0.0400 | -0.0300 | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 22-11-16 | 23-02-16 | 23-08-31 | 23-11-09 | 24-02-15 | 24-05-14 | - | - | - |
1SEK in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | 53.7 | - | 15.9 | 11.2 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -44.5 | - | -48.1 | -75 | -81.4 | -52 | -3 | - |
| ROE (net income / shareholders' equity) | -56.5% | - | -56.6% | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | - | - | - | - | - | 1 | 2 | - |
| Capex / Sales | - | - | - | - | - | 1.84% | 1.13% | - |
| Announcement Date | 20-02-20 | 21-04-20 | 22-02-17 | 23-02-16 | 24-02-15 | - | - | - |
1SEK in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
| 1st Jan change | Capi. | |
|---|---|---|
| -27.52% | 16.33B | |
| -40.04% | 2.96B | |
| +15.16% | 1.82B | |
| -6.86% | 1.55B | |
| +38.67% | 1.41B | |
| -15.36% | 976M | |
| -26.08% | 846M | |
| +3.53% | 811M | |
| -24.63% | 631M |
- Stock Market
- Equities
- ACARIX Stock
- 7AC Stock
- Financials Acarix AB
